Locus Capital Advisors · 基點資本有限公司

We position at the locus. Before the expression.

Family Office Advisory · Hong Kong

Scroll
The Investment Thesis

Three structural dislocations
the market consistently misprices

01
The Valuation Gap
Traditional financial metrics — P/E ratios, EBITDA multiples — are structurally useless for clinical-stage companies. The market consistently fails to accurately price Clinical Probability of Success, creating asymmetric entry points for disciplined investors who can read the science.
02
The Patent Cliff
Large Pharma faces over $200 billion in revenue losses from patent expirations by 2030. Acquisition of innovative biotech is existential — not optional. This creates a structural floor under valuations and a powerful M&A tailwind that defines our commercial-stage thesis.
03
Information Asymmetry
Biotech volatility is retail-sentiment driven. We identify when and why the market overreacts — distinguishing a fixable FDA Complete Response Letter from a fundamental scientific failure, or a clinically successful trial that is commercially unviable from one that is not.
04
The Catalyst Window
Value in biopharma is not realised gradually — it snaps in the 3–12 month window surrounding clinical readouts and regulatory decisions. We position precisely ahead of these moments, capturing the re-rating rather than chasing it.
Investment Strategy

A high-conviction catalyst-capture model
with a dual-track return profile

70%
Development Stage
Phase 2/3 clinical assets
30%
Commercial Stage
M&A targets
The Engine — Development Stage
Concentrated positions in Phase 2/3 clinical-stage assets. We build exposure 3–12 months before major catalyst events — clinical readouts, PDUFA dates, regulatory decisions — and hold through the re-rating. Position sizing is capped at 10% at cost to preserve capital while maintaining meaningful concentration.
The Anchor — Commercial Stage
Approved assets and strategic M&A targets — particularly those positioned to benefit from large pharma's patent cliff. These positions provide lower volatility and the opportunity to capture 50–100% acquisition premiums. The anchor stabilises the portfolio while the engine generates asymmetric upside.
Covered Calls
10–20% annualised premium income on core holdings during wait-and-see periods between catalysts.
Cash-Secured Puts
Precision entry into high-conviction names at a meaningful discount, systematically lowering cost basis.
Put Spreads
Defined downside protection through binary event windows where the risk-reward justifies holding.
Scientific Due Diligence

Underwriting therapeutic value
through a four-factor framework

01
MoA Validation
Is the underlying biology mechanistically sound? We evaluate the mechanism of action for scientific credibility before any financial analysis.
02
Clinical Utility
Does this asset address a massive unmet medical need? We focus on indications where current standard of care is inadequate — oncology, immunology, rare disease.
03
Regulatory Path
Is the FDA's primary endpoint achievable with the trial design? We model approval probability with granular attention to endpoint selection and precedent.
04
Commercial Viability
Will payers actually cover this drug at a price that supports the investment thesis? A clinically successful drug with poor reimbursement prospects is not an investment.
Account Structure

Full transparency.
No black box.

Direct Custody
Assets are held in your name at top-tier brokerages — Interactive Brokers preferred. You retain full legal ownership at all times. We have no custody or control over your assets beyond trading authority.
Real-Time Transparency
100% visibility into every trade and holding through your own brokerage platform. No black-box reporting, no aggregated NAV statements — you see exactly what we do, when we do it.
Enhanced Liquidity
No lock-up periods, no redemption gates. One month's notice is requested for significant withdrawals to allow optimal capital rebalancing — but your capital is accessible.
Tax Efficiency
Direct ownership enables personalised tax-loss harvesting strategies tailored to your specific tax position — a significant advantage over commingled fund structures.
The Team

Finance meets science.
Conviction meets execution.

Managing Partner
Eddie Lee
李哲宇
CFA · FRM
Over 20 years of institutional financial and risk management and family office governance. Currently serves as Principal Advisor for a Single-Family Office, where he manages and executes this specific biotech investment strategy for the principal's private holdings. Combines institutional risk management with Dr. Ho's scientific insights to make final capital allocation and execution decisions.
UC Berkeley EECS HKUST MBA
Strategic Advisor
Dr. Dennis Ho
何思朗
PhD (Genetics) · CFA
Senior biopharma executive with 20+ years of experience at Amgen, Roche, Exact Sciences, and Guardant Health. Led strategy for gene therapy and oncology product launches. Provides the deep technical and scientific diligence that underpins the portfolio's catalyst selection. Serves in an exclusive advisory capacity, guiding the scientific conviction of the strategy.
Harvard PhD Genetics MIT
Get In Touch

Begin the
conversation.

Email
eddie@locuscapitaladvisors.com
Hong Kong
+852 5600 0313
Mainland China
+86 1392 250 1089
Taiwan
+886 0931 079 988
Office
Hong Kong SAR
Request a strategy overview
We work with a select number of UHNW families and family offices. If you are interested in learning more about our biopharma event-driven strategy or family office advisory services, we welcome a direct conversation.
Send a message